10-K

Company

Kalaris Therapeutics, Inc.

Filed

February 12, 2021

Period of Report

December 31, 2020

Accession Number

0001564590-21-005652

A 10-K is a company's comprehensive annual report, required by the SEC. It includes audited financial statements, a description of the business, risk factors, and management's discussion of results. Learn more about 10-K filings →